Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update.

Patel DA, Akinsete AM, de la Fuente J, Kassim AA.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30025-X. doi: 10.1016/j.hemonc.2020.01.002. [Epub ahead of print] Review.

2.

Hematopoietic stem cell transplantation for patients with sickle cell disease in the Eastern Mediterranean.

Alahmari AD, Aljurf M, Alseraihy A, Hamidieh AA, Alkindi S, Rihani R, Satti T, Alsaedi H, Almohareb F, Al-Jefri A, Rasheed W.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30023-6. doi: 10.1016/j.hemonc.2020.02.002. [Epub ahead of print] Review. No abstract available.

3.

Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe.

Temerik DF, El-Mahdy WT, Ahmed AM.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30020-0. doi: 10.1016/j.hemonc.2020.02.001. [Epub ahead of print]

4.

Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?

de Udaeta MP, Diaz-Ricart M, Carreras E.

Hematol Oncol Stem Cell Ther. 2020 Mar 13. pii: S1658-3876(20)30022-4. doi: 10.1016/j.hemonc.2019.12.005. [Epub ahead of print] Review.

5.

Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.

Foell J, Kleinschmidt K, Jakob M, Troeger A, Corbacioglu S.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30024-8. doi: 10.1016/j.hemonc.2019.12.006. [Epub ahead of print] Review.

6.

Proceedings of the meeting of the Pediatric Disease Working Party (PDWP) of the European group for Blood and Marrow Transplantation (EBMT) on sickle cell disease 16-17 May 2019, Regensburg, Germany.

Corbacioglu S, Gluckman E, Alahmari A, Kassim A, de la Fuente J.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30016-9. doi: 10.1016/j.hemonc.2019.12.001. [Epub ahead of print] No abstract available.

7.

Should young children with human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation?

Krishnamurti L.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30027-3. doi: 10.1016/j.hemonc.2019.12.008. [Epub ahead of print]

8.

Standard management of sickle cell disease complications.

Abboud MR.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30026-1. doi: 10.1016/j.hemonc.2019.12.007. [Epub ahead of print] Review.

9.

Status quo of allogeneic stem cell transplantation for patients with sickle cell disease using matched unrelated donors.

Oevermann L, Sodani P.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30019-4. doi: 10.1016/j.hemonc.2019.12.004. [Epub ahead of print] Review.

10.

What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?

Bernaudin F.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30017-0. doi: 10.1016/j.hemonc.2019.12.002. [Epub ahead of print] Review.

11.

Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16-17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Oostenbrink LVE, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Pool ES, van Halteren AGS, Moes DJAR, Bredius RGM, Mohseny AB, Smiers FJW, van Tol MJD, Schilham MW, Lankester AC.

Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30018-2. doi: 10.1016/j.hemonc.2019.12.003. [Epub ahead of print]

12.

Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.

Gluckman E, Cappelli B, Scigliuolo GM, De la Fuente J, Corbacioglu S.

Hematol Oncol Stem Cell Ther. 2020 Mar 16. pii: S1658-3876(20)30034-0. doi: 10.1016/j.hemonc.2019.12.011. [Epub ahead of print] Review.

13.

Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review.

Khalid F, Damlaj M, AlZahrani M, Abuelgasim KA, Gmati GE.

Hematol Oncol Stem Cell Ther. 2020 Mar 16. pii: S1658-3876(20)30032-7. doi: 10.1016/j.hemonc.2020.02.003. [Epub ahead of print]

14.

How to setup a successful transplant program for hemoglobinopathies in developing countries: The Cure2Children approach.

Faulkner L.

Hematol Oncol Stem Cell Ther. 2020 Mar 16. pii: S1658-3876(20)30033-9. doi: 10.1016/j.hemonc.2019.12.010. [Epub ahead of print] Review.

15.

Curative options for sickle cell disease in Africa: Approach in Tanzania.

Makani J; Sickle Cell Programme, Muhimbili University of Health and Allied Sciences.

Hematol Oncol Stem Cell Ther. 2020 Mar 16. pii: S1658-3876(20)30038-8. doi: 10.1016/j.hemonc.2019.12.012. [Epub ahead of print] Review. No abstract available.

16.

Philadelphia chromosome-positive T-cell acute lymphoblastic leukemia: A case report and review of the literature.

Alshomar A, El Fakih R.

Hematol Oncol Stem Cell Ther. 2020 Mar 16. pii: S1658-3876(20)30036-4. doi: 10.1016/j.hemonc.2020.02.004. [Epub ahead of print] No abstract available.

Supplemental Content

Loading ...
Support Center